U.S. Blood Plasma Collection Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

U.S. Blood Plasma Collection Market Size

• The U.S. blood plasma collection market size was valued at USD 5.50 billion in 2024 and is expected to reach USD 8.97 billion by 2032, at a CAGR of 6.3% during the forecast period
• The market growth is largely fueled by the increasing demand for plasma-derived therapies to treat chronic and life-threatening conditions such as hemophilia, immune deficiencies, and neurological disorders, which is prompting expansion in plasma collection infrastructure across the U.S.
• Furthermore, the rise in government and private sector investments in plasma collection centers, along with technological advancements in apheresis devices and cold chain logistics, are accelerating the efficiency and reliability of U.S. blood plasma collection solutions, thereby significantly boosting the industry's growth

U.S. Blood Plasma Collection Market Analysis

• Blood plasma collection, which involves extracting vital components like immunoglobulins and clotting factors, has become a cornerstone of modern therapeutic solutions in the U.S. healthcare system, particularly for treating rare, chronic, and immune-related disorders. Its increasing relevance stems from the surging demand for plasma-derived therapies across both public and private healthcare sectors
• The growing need for immunoglobulin therapies, advancements in plasmapheresis technology, and government initiatives supporting biologics manufacturing are major factors fueling the demand for efficient plasma collection infrastructure across the U.S.
• The automated plasma collection segment dominated the largest market revenue share of 68.9% in 2024, driven by its improved efficiency, higher plasma yield, and enhanced donor comfort compared to manual methods

Report Scope and U.S. Blood Plasma Collection Market Segmentation         

U.S. Blood Plasma Collection Market Trends

“Advancements in Plasma Collection Technology and Network Expansion”

• A key and accelerating trend in the U.S. blood plasma collection market is the continuous advancement of plasmapheresis technology and the strategic expansion of donation center networks by leading players. These innovations are significantly enhancing donor experience, improving operational efficiency, and increasing plasma yield per session
• For instance, major providers like CSL Plasma, Grifols, BioLife, and Octapharma are investing in next-generation automated plasmapheresis systems that reduce donation time and improve donor comfort. These technological upgrades are vital for encouraging repeat donations and optimizing throughput in high-volume donation centers
• In addition, the expansion of collection centers across underserved and high-demand regions is boosting donor accessibility and strengthening the national plasma supply chain. Companies are also leveraging mobile plasma units and partnerships with local healthcare providers to broaden their geographic reach and engage new donor populations
• The integration of digital scheduling, biometric check-in systems, and real-time donor tracking further enhances efficiency and regulatory compliance, aligning with FDA and cGMP guidelines. These measures support improved plasma quality and safety, while also streamlining operations across large collection networks
• This push toward technology-enabled, patient-centric plasma collection models is reshaping the U.S. market landscape. As demand for plasma-derived therapies grows, especially for treating immunodeficiencies and neurological disorders, the market is expected to witness sustained growth through expanded infrastructure and process optimization

U.S. Blood Plasma Collection Market Dynamics

Driver

“Growing Demand for Plasma-Derived Therapies and Expanded Collection Infrastructure”

• The increasing prevalence of chronic and life-threatening conditions such as immunodeficiencies, hemophilia, and liver diseases is significantly driving demand for plasma-derived therapies in the U.S. market
• For instance, in February 2024, CSL Plasma announced the expansion of its network by opening multiple state-of-the-art plasma collection centers across the Midwest, aimed at increasing national plasma supply for therapeutic use. Such initiatives by leading players are expected to drive the U.S. Blood Plasma Collection industry growth during the forecast period
• As healthcare systems and pharmaceutical companies increase their reliance on plasma-based biologics, there is a rising need for consistent and safe plasma collection processes, enhancing investments in donor outreach and modern collection centers
• Furthermore, government support, coupled with FDA regulations ensuring safe donor practices and product quality, reinforces consumer confidence and supports large-scale plasma collection efforts
• Innovations such as automated apheresis systems, digital donor tracking platforms, and integration of mobile applications for scheduling and rewards are also contributing to the rising participation of donors and operational efficiency across the U.S. blood plasma collection industry

Restraint/Challenge

“Donor Recruitment Challenges and High Operational Costs”

• One of the significant challenges in the U.S. blood plasma collection market is the difficulty in attracting and retaining regular donors. Donor fatigue, misinformation about the process, and limited awareness of plasma’s role in critical therapies often reduce repeat donations
• For instance, several industry reports have cited fluctuations in donor turnout during 2023–2024 due to inflation-related economic instability and shifting public health priorities post-COVID-19
• In addition, setting up and maintaining plasma collection centers involve high infrastructure costs, including medical-grade equipment, trained staff, and compliance with stringent regulatory protocols enforced by the FDA and other health agencies
• Unlike standard blood donation, plasma collection is more time-consuming and requires advanced systems such as plasmapheresis machines, further raising operational expenses
• Overcoming these barriers will require industry-wide donor education campaigns, incentive-based recruitment programs, and technological upgrades to streamline the donation process. Financial support and partnerships with healthcare providers may also help mitigate costs and improve long-term sustainability

U.S. Blood Plasma Collection Market Scope

The market is segmented on the basis of type, product type, method, application, and end user.

• By Type

On the basis of type, the U.S. blood plasma collection market is segmented into recovered plasma and source plasma. The source plasma segment dominated the market with a 74.6% revenue share in 2024, driven by its critical role in producing life-saving plasma-derived therapies such as immunoglobulins and clotting factors.

The recovered plasma segment is expected to witness the fastest CAGR from 2025 to 2032, primarily used in whole blood donations and specific hospital-based transfusions, especially in low-volume collection settings.

• By Product Type

On the basis of product type, the U.S. blood plasma collection market is segmented into needles and syringes, collection tubes, and others. Needles and syringes accounted for the largest share of 48.2% in 2024, supported by consistent and high-volume usage across all plasma collection procedures.

Collection tubes is expected to witness the fastest CAGR from 2025 to 2032, fueled by increasing automation and precision diagnostics.

• By Method

On the basis of method, the U.S. blood plasma collection market is segmented into automated plasma collection and manual plasma collection. Automated plasma collection led the market with a 68.9% share in 2024, owing to improved efficiency, higher yield, and greater donor comfort.

Manual plasma collection is expected to witness the fastest CAGR from 2025 to 2032 as it is remains relevant in smaller donation setups and resource-constrained environments.

• By Application

On the basis of application, the U.S. blood plasma collection market is segmented into molecular biology, sample recovery, blood glucose analysis, hematological analysis, and others.

Hematological analysis dominated with a 34.7% share in 2024, driven by demand for routine diagnostics and blood disorder screening.

Molecular biology is expected to register the fastest CAGR of 8.5% from 2025 to 2032, due to increased genetic testing and infectious disease diagnostics.

• By End User

On the basis of end user, the U.S. blood plasma collection market is segmented into hospitals, pathology labs and diagnostic centers, blood banks, and others. Blood banks held the highest share of 42.3% in 2024, owing to their central role in large-scale plasma collection and distribution.

Pathology labs and diagnostic centers is expected to witness the fastest CAGR from 2025 to 2032 as they expand in-house collection and diagnostic services.

U.S. Blood Plasma Collection Market Regional Analysis

• The U.S. held a market share of 79.2% in the North America in blood plasma collection market in 2024, driven by advanced healthcare infrastructure, a high number of FDA-certified plasma collection centers, and a growing demand for plasma-derived therapies for immunodeficiencies, hemophilia, and autoimmune diseases
• The country’s robust regulatory support from bodies like the U.S. Food and Drug Administration (FDA) and active participation in public awareness programs have contributed significantly to the expansion of donor pools and improved plasma availability

U.S. Blood Plasma Collection Market Share

The U.S. blood plasma collection industry is primarily led by well-established companies, including:

• STRECK (U.S.)
• SIO2 Material Science (U.S.)
• Grifols (Spain)
• Instech Laboratories, Inc. (U.S.)
• CSL Plasma (Australia)
• Greiner Bio-One International GmbH (Austria)
• Cardinal Health (U.S.)
• Retractable Technologies, Inc. (U.S.)
• BD (U.S.)
• Bio Products Laboratory Ltd. (U.S.)
• Hemarus Plasma (U.S.)
• Liminal Biosciences, Inc. (Canada)
• Vitalant (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Octapharma AG (Switzerland)
• Kedrion (Italy)

Latest Developments in U.S. Blood Plasma Collection Market

• In March 2022, the U.S. Food and Drug Administration (FDA) approved a new plasma collection system developed by Terumo Blood and Cell Technologies (Terumo BCT), a leading medical technology company. Named Rika, this next-generation automated system is designed to enhance the experience of both plasma center staff and donors. It features built-in safety mechanisms to reduce operator errors and can collect plasma in 35 minutes or less. Rika was set to launch in the spring through a limited market release at CSL Plasma collection centers in the Denver, Colorado area, with broader deployment planned across additional CSL Plasma locations later in 2022.
• In June 2021, Cardinal Health Nuclear & Precision Health Solutions secured FDA approval for LYMPHOSEEK Paediatric Indication, propelling company growth in the blood plasma collection market, with expanded offerings catering to pediatric patients, strengthening market demand and revenue
• In June 2021, Octapharma AG's octagam gained European and German approvals for dermatomyositis in adults, augmenting the company's presence in the blood plasma collection market, particularly in Europe and Germany. This diversification strengthens market competitiveness and revenue potential

SKU-64204